RxDoctor Payments Data

Elahe Mohazab

Nurse Practitioner · Austell, GANPI 1770993610

Payments from drug & device makers

$5,422in general payments, 2019–2025

Across 68 payments — averaging $79.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$882
  • AbbVie$859
  • Neurocrine Biosciences, Inc.$715
  • Otsuka America Pharmaceutical, Inc.$592
  • Alkermes, Inc.$508
  • Supernus Pharmaceuticals, Inc.$436
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$5,422100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,422 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$9,758
Medicare patients
19
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine28$235,020
VraylarCariprazine Hcl17$21,591
Chlorpromazine Hcl41$9,719
Aripiprazole75$1,289
Risperidone58$1,135
Ziprasidone Hcl37$1,049
Mirtazapine72$1,023
Olanzapine28$657
Lamotrigine55$565
Fluoxetine Hcl73$559
Venlafaxine Hcl ErVenlafaxine Hcl24$557
Trazodone Hcl84$537
Sertraline Hcl101$535
Atomoxetine Hcl15$508
Duloxetine Hcl29$507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$218$235,02028 claims
AbbVieVraylar$859$21,59117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Austell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →